Landiolol Hydrochloride

盐酸兰地洛尔

Report date: 2024/11/29 11:38:54
NME

Base Information

Drug NameLandiolol Hydrochloride
Drug Alias NameLandiololumCorebetaOnoactRapiblocRapiblyk +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-1 adrenergic receptor antagonists
TargetsBeta-1 adrenergic receptor
Therapy Area/IndicationsPostoperative ComplicationsCoronary Artery DiseaseHeart Arrest +[9] 
Global Approved IndicationsTachycardia, SinusTachycardia, SupraventricularAtrial Flutter +[6] 
Approved Indications in ChinaArrhythmias, Cardiac
Original Approved Country/TerritoryJapan
Original Approved Date2002/07/05
Country/TerritoryCzechiaUnited StatesAustria +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAop Orphan Pharmaceuticals GmbHEagle Pharmaceuticals IncMedical University Of Vienna +[5] 
Inactive CompaniesAop Orphan Pharmaceuticals AgOno Pharma Usa IncGuangdong Sunho Pharmaceutical Co Ltd +[4] 
Active IndicationsHeart ArrestTachycardia, SinusTachycardia, Supraventricular +[7] 
Inactive IndicationsPostoperative ComplicationsCoronary Artery Disease

Other Information

ATC CodeC07AB14
Related LinksWikipediaDrugBankKEGG